Floatz logo

Interleukin 18 (recombinant human mutein clone ST-067)

Squamous Cell Carcinoma of the Head and Neck

Simcha IL-18, Inc.protein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

249 Active assets in the Squamous Cell Carcinoma of the Head and Neck cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Carboplatin
Akeso
Phase 4BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB

View all 50 →

Same molecule, other indications

Interleukin 18 (recombinant human mutein clone ST-067) is also rated in:

follicular lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
high grade B-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →